Home > Focus Areas > COPD Connect > Post
  • Saved

1yr
Case Study: Optimizing COPD Maintenance Therapy for a 68-Year-Old Patient

A 68-year-old male with a 10-year history of COPD presents for a follow-up visit. The patient’s symptoms have been managed with short-acting bronchodilators, but he reports increasing dyspnea over the last six months and frequent use of rescue inhalers. His spirometry results show a FEV1 of 55% predicted, consistent with moderate COPD. He has experienced two exacerbations in the past year, one requiring hospitalization.

The patient is currently on a short-acting bronchodilator regimen but continues to experience symptom progression and exacerbations. His primary concern is reducing the frequency of exacerbations and improving daily lung function. How should his maintenance therapy be optimized?

The GOLD guidelines recommend initiating maintenance therapy with long-acting bronchodilators for patients with moderate to severe COPD. Long-acting bronchodilators, including both beta-agonists and anticholinergics, have been shown to improve lung function, reduce exacerbations, and enhance quality of life. Transitioning to a once-daily long-acting regimen could simplify the patient’s management and reduce the need for frequent rescue inhaler use. The choice between single-agent or dual bronchodilator therapy should be based on the patient’s exacerbation history and symptom burden.

Given this patient’s exacerbation history and declining lung function, how would you approach his maintenance therapy? Would you initiate monotherapy with a long-acting bronchodilator or consider dual bronchodilation for optimal control, and why?

  • 1yr
    because of low spirometry reading and sob with exacerbations i would get eosinophil level and start on triple therapy until patient improves than maybe switch to double therapy
  • 1yr
    Change to LAMA/LABA and add ICS if needed.
  • 1yr
    Given the patient’s moderate COPD, increasing symptoms, and two exacerbations in the past year (one requiring hospitalization), dual bronchodilation with a LABA + LAMA combination is the most appropriate maintenance therapy. This approach will improve lung function, reduce exacerbation frequency, and simplify treatment with once-daily dosing. Dual bronchodilators are more effective than monotherapy in patients with frequent exacerbations and significant symptoms. Regular follow-up is essential to assess symptom control, adherence, and potential need for further adjustments.
  • 1yr
    I would add a triple and to be specific would add Breztri for its mortality reduction data
  • 1yr
    Adding the long acting option in a combination has historically been the most effective option in this patient population either dual or triple therapy working somewhat similarly
  • 1yr
    Without chronic cough or sputum symptoms I would give LAMA/LABA therapy. I am not sure triple therapy would be much better for this particular patient up front, but if I only had triple therapy samples I would be willing to start the patient on the samples and reevaluate on follow up visit .
  • 1yr
    significant clinical change over the last year with at least one severe exacerbation. would likely go for a combination of triple therapy and roflumilast while phenotyping his eosinophils. Would likely choose a combination that included budesonide, for the potentially lower pneumonia risk (so either Breztri, or some other similar divided combination).
  • 1yr
    pt needs at least long acting inhalwr such has anoro,if high eosinophils than TRELEY INSTEAD OF ANORO
  • 1yr
    Triple therapy
  • 1yr
    laba/lama. (Check eos)
  • 1yr
    Laba/lama at minimum. Consider ICS if asthmatic component.
  • 1yr
    I would agree with others and start a LABA/LAMA combination such as Stioloto. Also use short acting agents (SABA) prn. Avoid ICS for now.
  • 1yr
    Given 2 exacerbations in the last 1 year, triple therapy should be considered. If blood eos are low (less than or equal to 100 cells/uL), LABA/LAMA could be considered
  • 1yr
    LAMA LABA dual inhaler and triple if not controlled
  • 1yr
    Would start on LABA/LAMA for maintenance and continue SABA prn. If symptoms persist then will consider triple therapy.
  • 1yr
    LABA/LAMA would by my inclination; with a low threshold for ICS at least until stable. If has reactive airway symptomatology or other pertinent marker (elevated eos etc) I'd probably go ahead with ICS/LABA/LAMA. needs to be up to date on vaccinations, trigger monitoring etc
  • 1yr
    Clinically this patient Grade 2 and Class E - will definitely start with a dual therapy of Lana/lama and may consider starting additinal ICS if peripheral Eos > 300.
  • 1yr
    With 1 hospitalization, patient should be started on a LABA/LAMA and continued on PRN SABA
  • 1yr
    Since the patient has had trouble already then triple therapy keeps the patient out of trouble better from my experience.
  • 1yr
    The main concern with use of ICS is the increased risk of pneumonia. I would definitely start LAMA/LABA therapy along with SABA and then assess improvement in lung function. Would only consider additional ICS therapy if still experiencing exacerbations or symptoms or no no improvement in lung function
  • 1yr
    because 2 exacerbation and poor spirometry i would start patient on triple therapy
  • 1yr
    It is surpising to see in this vignette that has 10 years history of COPD pt has been on SABA only and with moderate COPD should have been on the maintenance therapy all along and could have prevented the exacerbation and the hospitalization ! In any case right now he defintely needs the tripple therapy and the best option for single one dose would be Trelegy which has robust data to back it up and consistent with GOLD guidelines too the other option would be Breztri for twice daily dosing if Trelegy has issues with coverage cost and the choice of the device for a particular patient , once maintenance has been achieved well then consideration can be given to titrate down to LAMA/ LABA combination inhaler due course of time to prevent the long term ICS use

Show More Comments